GLPwatch
Papers (10389)
Page 150 of 174, ranked by citation count.
- THR-β Agonists vs Incretin Therapies for Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Biopsy-Anchored Systematic Review With Grading of Recommendations Assessment, Development and Evaluation (GRADE) Certainty.
- Diabetes medications improve cardiovascular outcomes: the paradigm shifts.
- Chronic Liraglutide Administration Fails to Suppress Postprandial Glucagon Levels in Type 1 Diabetic Islet Allograft Recipients With Graft Dysfunction.
- Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications.
- [Nephroprotection in patients with diabetes mellitus].
- Three-year changes in renal function after switching from injectable GLP-1 receptor agonists to oral semaglutide in Japanese patients with type 2 diabetes: a retrospective cohort study.
- Preferred Glucagon-like Peptide-1 Receptor Agonists in Adults With Type 2 Diabetes and Established Cardiovascular Disease or High Cardiovascular Risk: A Network Meta-analysis of Randomized Trials.
- GLP-1-based therapy and ICD-10-documented heart failure or respiratory failure events in non-diabetic adults with rheumatoid arthritis and obesity: a TriNetX federated cohort study.
- [Basal insulin glargine-lixisenatide fixed ratio combination (Suliqua®)].
- [Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes].
- Effects of lixisenatide treatment on mild cachexia and related metabolic abnormalities in Walker-256 tumour-bearing rats.
- Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians.
- Comparative Effects of Dulaglutide and Semaglutide on Renal Function Decline and Proteinuria Reduction in Diabetic Patients: A Retrospective Cohort Study.
- Paradigm Shifts to Improve Treatment in Youth with Type 2 Diabetes.
- Body image in the age of GLP-1s: Emerging questions for research and practice.
- IgG Fc-Binding Motif-Conjugated Exendin-4: A Long-Acting Hypoglycemic Agent via Broad-Spectrum Antibody Engagement for Type 2 Diabetes Therapy.
- Economic evaluation of sodium-glucose transporter 2 inhibitors compared with glucagon-like peptide 1 receptor agonist for the treatment of type 2 diabetes: a systematic review.
- Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic Control.
- Resolution of severe lumbar spinal epidural lipomatosis following tirzepatide-induced weight loss: illustrative case.
- GLP-1 receptor agonist properties of a chimeric peptide derived by hybridization of Latrodectus αLatrotoxin and Heloderma Exendin-4.
- [Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes].
- [GLP-1 agonists - new kid on the block in nephrology].
- Improved quality of life with semaglutide in schizophrenia: Secondary analyses from a randomized controlled trial.
- A bifunctional anti-PCSK9 scFv/Exendin-4 fusion protein exhibits enhanced lipid-lowering effects via targeting multiple signaling pathways in HFD-fed mice.
- Bariatric surgery and semaglutide in a youth with juvenile Huntington disease and severe obesity: a case report.
- [A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide].
- Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.
- South African Hypertension Society 2012 congress report.
- Exploring the off-label use of liraglutide in the treatment of obesity: a review.
- Sintilimab-related fulminant autoimmune diabetes mellitus manifesting as diabetic ketoacidosis and rare insulin resistance: A case report and literature review.
- Adding liraglutide to diet and exercise to maintain weight loss - is it worth it?
- Dulaglutide-associated body odor with dechallenge and rechallenge in a patient with type 2 diabetes.
- Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review.
- Obesity Week 2016 Annual Meeting.
- [EFFECTS OF ORALLY AND PARENTERALLY ADMINISTERED ANALOGS OF PEPTIDE HORMONES ON RENAL WATER AND ION TRANSPORT].
- The Welander TIA1 mutation dedifferentiates insulin-producing cells: Reversal by a GLP-1 receptor agonist.
- Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.
- Real-World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non-Diabetic Adults.
- [Effects of Exendin-4 on the differentiation of neural stem cells from subventricular zone of adult mice in vitro].
- Effectiveness of a Psychiatrist-Led Clinic for Metabolic Health in Severe Mental Illness: A Retrospective Chart Review Study.
- The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms.
- GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.
- Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability.
- Combining GLP-1 Receptor Agonists and Health-Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real-World Single-Center Study.
- Heart failure with preserved ejection fraction: updated diagnostic and therapeutic strategies. SEMI consensus document.
- [Effect and mechanism of liraglutide on the apoptosis of human hepatocellular carcinoma HepG2 cells induced with palmitic acid].
- Magnitude and Determinants of Weight Loss Response to GLP-1/GIP Receptor Agonists in India: A Real-World Time-to-Event Analysis.
- The future use of liraglutide: implications of the LEAD-2 study for treatment guidelines in type 2 diabetes.
- dulaglutide (Trulicity°) weekly in type 2 diabetes: Cardiovascular reactions should be better documented.
- Real-world outcomes of hybrid obesity care using digital coaching and GLP-1 therapy in a multi-ethnic Asian setting.
- Do GLP-1 receptor agonists improve insulin sensitivity and reduce lipid accumulation in skeletal muscles and the liver independent of weight loss?
- Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.
- [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
- Effects of Agonists on Skin Quality: A Comprehensive Literature Review.
- NEW FOR YOU! These innovative products aim to help make diabetes self-management easier.
- [Pharmacological treatments for obesity : what does the future hold?]
- Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP-1 Receptor Agonist Therapy.
- TikTokfluence: The rise of GLP-1 receptor agonists in the age of social media health trends.
- Evaluating the managed care implications of longer-acting basal insulin analog therapies.
- Semaglutide for treatment of intractable diarrhea of different etiologies: a case series of 30 patients.